Coagulase-negative Staphylococci
Conditions
Interventions
Control group (Clinical treatment plan):None
Experimental group (The targeted antibacterial treatment carried out after the detection of CoNS):None
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. From January 1, 2024 to December 31, 2025, patients who were hospitalized in our hospital, and during which any clinical specimens (blood, body fluids, tissues, etc.) cultured CoNS, and whose electronic medical records and nursing records were complete and available for data extraction. 2. Age >= 18 years old; 3. The strain was confirmed and preserved by the microbiology laboratory. 4. Within 24 hours after the detection of CoNS, patients who began the antibacterial drug treatment for this CoNS (the experimental group); 5. From the time of detecting CoNS until discharge or the main observation endpoint, no systemic antibacterial drugs targeting CoNS were administered (in the control group).
Exclusion criteria
Exclusion criteria: 1. Clinical data is severely lacking: Key information such as baseline characteristics, primary outcome indicators (survival status), and records of antibiotic use cannot be obtained from the electronic medical records, making it impossible to conduct effective analysis. 2. Unable to evaluate treatment decisions or clinical outcomes: Discharged, transferred to another hospital, or died within 24 hours after the detection of CoNS. 3. There are severe interfering concurrent infections: Within 24 hours prior to or simultaneously with the detection of CoNS, there were already other definite infections that required potent broad-spectrum antibacterial treatment (such as invasive aspergillosis, etc.), making it impossible to attribute the clinical outcome. 4. The treatment status could not be clearly classified: Within the "treatment decision window period" of 24 hours after the detection of CoNS, antibacterial treatment was initiated, but this treatment was not specifically targeted at CoNS (that is, based on the drug sensitivity report, the drugs used were ineffective or did not have the conventional activity against the detected CoNS strains); 5. Repetitive isolates from the same patient and the same site (the first isolation is retained); 6. High probability of contamination/colonization: This includes cases where a single blood culture report shows CoNS positivity, and the doctor in the clinical record clearly indicates that it was determined to be contamination; cases where CoNS is detected only from a non-sterile site (such as sputum, throat swab, superficial wound swab), and the patient has no corresponding local or systemic infection symptoms or signs (such as fever, purulent discharge, imaging infiltrates, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 30-day all-cause mortality rate;Effective rate of treatment for infectious diseases; | — |
Secondary
| Measure | Time frame |
|---|---|
| Medical resource consumption;Adjustment period of antibacterial drugs;Initial treatment efficacy;In-hospital mortality rate; | — |
Countries
China
Contacts
Public ContactLi Jie
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed